Plain-English translation of NCT07186296 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →The EMERALD study is testing a new technology called ExoPred that analyzes tiny particles in your blood to detect five common cancers: lung, breast, colon, pancreatic, and ovarian cancer. Researchers will use your blood sample to train and validate this detection tool, which could eventually help doctors catch these cancers earlier when they may be easier to treat.
Most of these cancers are difficult to catch in early stages, when treatment is often most effective. This study aims to develop a simple blood test that could identify cancer before symptoms appear or before traditional screening methods catch it.
You likely qualify if…
You likely don't qualify if…
Your participation involves donating a single blood sample, which will be analyzed using the new detection technology. The study is divided into phases over time—your sample may be used to train the tool, test its performance, or validate it in a final blinded stage. Beyond the blood draw, there are no ongoing visits or treatments required, though you should be prepared to provide informed consent and allow researchers to access your medical information.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States